Enanta Pharmaceuticals Inc Revenue Growth Rates (ENTA), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Enanta Pharmaceuticals Inc  (NASDAQ: ENTA)
 

ENTA's Revenue Growth by Quarter and Year

Enanta Pharmaceuticals Inc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ENTA Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter September -
3rd Quarter June 14.36
2nd Quarter March 17.16
1st Quarter December 18.62
FY 50.14

ENTAs Annual Revenue
Enanta Pharmaceuticals Inc's Revenue in the fiscal year 2025 $ 65.32 millions
Enanta Pharmaceuticals Inc's Revenue in the fiscal year 2024 $ 67.64 millions
Enanta Pharmaceuticals Inc's Revenue in the fiscal year 2023 $ 79.20 millions
Enanta Pharmaceuticals Inc's Revenue in the fiscal year 2022 $ 86.16 millions
Enanta Pharmaceuticals Inc's Revenue in the fiscal year 2021 $ 97.07 millions




ENTA Revenue third quarter 2026 Y/Y Growth Comment
Enanta Pharmaceuticals Inc reported decline in Revenue in the third quarter 2026 by -21.58% to $ 14.36 millions, from the same quarter in 2025.
The contraction in the third quarter 2026 Enanta Pharmaceuticals Inc's Revenue compares unfavorably to the Company's average Revenue doubling of 114.66%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 120 other companies have achieved higher Revenue growth. While Enanta Pharmaceuticals Inc' s Revenue fall of -21.58% ranks overall at the positon no. 2590 in the third quarter 2026.


ENTA Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter September - 3.56 % -22.82 % -6.84 %
3rd Quarter June -21.58 % 1.89 % -4.87 % -3.03 %
2nd Quarter March 14.94 % -12.43 % -4.21 % -4.91 %
1st Quarter December 9.79 % -5.78 % -23.7 % -14.68 %
FY   - -3.4 % -14.62 % -

Financial Statements
Enanta Pharmaceuticals Inc's third quarter 2026 Revenue $ 14.36 millions ENTA's Income Statement
Enanta Pharmaceuticals Inc's third quarter 2025 Revenue $ 18.31 millions Quarterly ENTA's Income Statement


ENTA Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter September - -17.37 % -18.7 % 0.21 %
3rd Quarter June -16.32 % 22.64 % 5.4 % 6.12 %
2nd Quarter March -7.84 % -11.97 % -5.28 % -24.54 %
1st Quarter December 23.07 % 16.08 % -4.91 % 16.09 %
FY (Year on Year)   - -3.4 % -14.62 % -


Back to ENTA Growth rate Comparisons >> Back to ENTA Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #121
Healthcare Sector #373
Overall #2590

Revenue Y/Y Growth Statistics
High Average Low
2867.33 % 114.66 % -92.61 %
(Mar 31 2015)   (Dec 31 2013)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #121
Healthcare Sector #373
Overall #2590
Revenue Y/Y Growth Statistics
High Average Low
2867.33 % 114.66 % -92.61 %
(Mar 31 2015)   (Dec 31 2013)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Enanta Pharmaceuticals Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
4834.55 % 200.37 % -95.71 %
(Mar 31 2012)  


ENTA's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Enanta Pharmaceuticals Inc disclosed fall in Revenue from the second quarter by -16.32% to $ 14.36 millions, from $ 17.16 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 142 other companies have achieved higher Revenue quarter on quarter growth. While Enanta Pharmaceuticals Inc's Revenue growth quarter on quarter, overall rank is 3139.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #143
Healthcare Sector #418
Overall #3139
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #143
Healthcare Sector #418
Overall #3139
Revenue Q/Q Growth Statistics
High Average Low
4834.55 % 200.37 % -95.71 %
(Mar 31 2012)  


ENTA's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Enanta Pharmaceuticals Inc disclosed fall in Revenue from the second quarter by -16.32% to $ 14.36 millions, from $ 17.16 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 142 other companies have achieved higher Revenue quarter on quarter growth. While Enanta Pharmaceuticals Inc's Revenue growth quarter on quarter, overall rank is 3139.


Enanta Pharmaceuticals Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 65.26 $ 69.21 $ 66.98 $ 65.32 $ 64.81
Y / Y Revenue Growth (TTM) 0.7 % 7.37 % 0.58 % -3.42 % -9.94 %
Year on Year Revenue Growth Overall Ranking # 3215 # 3067 # 776 # 2302 # 2247
Seqeuential Revenue Change (TTM) -5.71 % 3.33 % 2.54 % 0.8 % 0.53 %
Seq. Revenue Growth (TTM) Overall Ranking # 2590 # 2716 # 650 # 2628 # 1808


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Enanta Pharmaceuticals Inc's cumulative twelve months Revenue were $ 65 millions, company would post below average annual Revenue growth of 0.53% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Enanta Pharmaceuticals Inc's Revenue growth from the 17.16% growth in Mar 31 2026.

In the Healthcare sector 425 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3067 to 3215.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 121
Healthcare Sector # 426
Overall # 3215

Revenue TTM Y/Y Growth Statistics
High Average Low
2867.33 %
 114.66 %
-92.61 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 121
Sector # 373
S&P 500 # 2590
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Enanta Pharmaceuticals Inc's cumulative twelve months Revenue were $ 65 millions, company would post below average annual Revenue growth of -92.61% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Enanta Pharmaceuticals Inc's Revenue growth from the 17.16% growth in Mar 31 2026.

In the Healthcare sector 425 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3067 to 3215.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 121
Healthcare Sector # 426
Overall # 3215

Revenue TTM Y/Y Growth Statistics
High Average Low
2867.33 %
114.66 %
-92.61 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 121
Sector # 373
S&P 500 # 2590




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ENTA's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Bio rad Laboratories Inc -0.05%$ -0.046 millions
Seer Inc -0.29%$ -0.289 millions
Dyadic International Inc -0.57%$ -0.568 millions
Teva Pharmaceutical Industries Limited-0.81%$ -0.814 millions
Aytu Biopharma Inc-0.91%$ -0.911 millions
Neuropace Inc -1.32%$ -1.323 millions
Ardent Health Inc -1.40%$ -1.400 millions
Sunshine Biopharma Inc -1.56%$ -1.557 millions
Pacific Biosciences Of California Inc -1.71%$ -1.706 millions
United Therapeutics Corporation-1.92%$ -1.916 millions
Orasure Technologies Inc-1.93%$ -1.930 millions
Pulmonx Corporation-1.93%$ -1.931 millions
Volitionrx Limited-1.97%$ -1.975 millions
Organon and Co -2.26%$ -2.258 millions
Airsculpt Technologies Inc -2.53%$ -2.527 millions
Charles River Laboratories International inc -2.72%$ -2.718 millions
Perrigo Company Plc-3.17%$ -3.171 millions
Zai Lab Limited-3.33%$ -3.333 millions
Vanda Pharmaceuticals Inc -3.92%$ -3.919 millions
Teladoc Health Inc -3.95%$ -3.952 millions
Dentsply Sirona Inc -4.06%$ -4.060 millions
Sanuwave Health Inc -4.18%$ -4.181 millions
Treace Medical Concepts Inc -4.24%$ -4.244 millions
Fortrea Holdings Inc -4.52%$ -4.519 millions
Positron Corporation-6.91%$ -6.907 millions
Standard Biotools Inc -7.05%$ -7.046 millions
Inspire Medical Systems inc -7.32%$ -7.316 millions
Adapthealth Corp -7.50%$ -7.505 millions
China Pharma Holdings Inc-7.55%$ -7.548 millions
Skinhealth Systems Inc -7.68%$ -7.680 millions


About Enanta Pharmaceuticals Inc Revenue Growth Rates (ENTA), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Enanta Pharmaceuticals Inc (CIK 1177648).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-345719
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Enanta Pharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.